# Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

Study · id `cardio:ct-nct02851745` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02851745](<https://clinicaltrials.gov/study/NCT02851745>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02851745

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

## Technical summary

Registry record NCT02851745. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2019-07-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 188 participants (enrolled count; ClinicalTrials.gov record NCT02851745, source copy `cardio:ctgov-nct02851745-2021-05-25`, retrieved 2026-10-26)
- Start date: 2015-07 (registry gives no type) (ClinicalTrials.gov record NCT02851745, source copy `cardio:ctgov-nct02851745-2021-05-25`, retrieved 2026-10-26)
- Primary completion: 2019-07-02 (actual) (ClinicalTrials.gov record NCT02851745, source copy `cardio:ctgov-nct02851745-2021-05-25`, retrieved 2026-10-26)
- Completion: 2019-07-02 (actual) (ClinicalTrials.gov record NCT02851745, source copy `cardio:ctgov-nct02851745-2021-05-25`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT02851745, source copy `cardio:ctgov-nct02851745-2021-05-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02851745-2021-05-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
- Acronym: DYDA2
- Condition: Diabetes Mellitus, Type 2
- Condition: Left Ventricular Systolic Dysfunction
- Intervention (Drug): Linagliptin
- Intervention (Drug): Placebo
- Lead sponsor: Heart Care Foundation
- Lead sponsor class: OTHER
- Collaborator: Fondazione dell'Associazione Medici Diabetologi
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial (`cardio:pubmed-33755143`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d7d911a47c843ec85465184701b71db80f2283aa702ef674214d259bb88ecdcd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
